News

The global antiviral drugs market size is expected to be worth around US$ 60.0 billion by 2030, according to a new report by Vision Research Reports.

The global antiviral drugs market size was valued at US$ 63.8 billion in 2020 and is anticipated to grow at a CAGR of -0.5% during forecast period 2021 to 2030.

Report Coverage

Report Scope	Details
Market Size	USD 60.0 billion by 2030
Growth Rate	CAGR of -0.5% From 2021 to 2030
Base Year	2021
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	Drug class, Type, Application
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned	Gilead Sciences, Inc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Cipla Inc.; Aurobindo Pharma; Dr. Reddy’s Laboratories Ltd.

Get Sample Copy of This Report@https://www.visionresearchreports.com/report/sample/38600

Growth Factors

 This is owing to the loss of patent protection of drugs and the high R&D investment required for developing antiviral drugs. However, the rising prevalence of viral infections and the presence of a potential pipeline for the treatment of HIV infection are expected to fuel the growth over the forecast period.

The increasing prevalence of influenza with other complications such as viral pneumonia, obesity, and the rising geriatric population drives the market growth. Moreover, pneumonia is one of the major causes of death in children worldwide. According to the WHO, Pneumonia causes 808,694 children’s deaths in 2017, accounting for 15.0% of all deaths of children under 5 years old. It is most prevalent in South Asia and the sub-Saharan African region.

Key Players

• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• AbbVie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.

Market Segmentation

• Drug Class
  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others
• Type
  • Branded
  • Generics
• Application
  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others
• Regional
  • North America
    • U.S
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Argentina
    • Brazil
    • Mexico
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa

Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38600 or call: +1 9197 992 333